OTCMKTS:PMCUF Pro Medicus (PMCUF) Stock Price, News & Analysis $127.04 0.00 (0.00%) (As of 11/14/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort Interest About Pro Medicus Stock (OTCMKTS:PMCUF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pro Medicus alerts:Sign Up Key Stats Today's Range$127.04▼$127.0450-Day Range$100.50▼$130.1152-Week Range$56.29▼$130.11VolumeN/AAverage Volume572 shsMarket CapitalizationN/AP/E Ratio8,469.33Dividend Yield0.02%Price TargetN/AConsensus RatingN/A Company OverviewPro Medicus Limited, a healthcare informatics company, engages in the development and supply of healthcare imaging software, and radiology information (RIS) system software and services to hospitals, imaging centers, and health care groups in Australia, North America, and Europe. The company offers Visage RIS Visage 7 Enterprise Imaging Platform, a healthcare imaging software that provides radiologists, physicians, and clinicians with access and visualization capability for viewing 2-D, 3-D, and 4-D medical images; and picture archive and communication system (PACS)/digital imaging software. It also provides Visage RIS, a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; Promedicus.net, an e-health platform for secure email and integration products. In addition, the company offers Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. The company was incorporated in 1983 and is headquartered in Richmond, Australia.Read More… 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Pro Medicus Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks0th Percentile Overall ScorePMCUF MarketRank™: Pro Medicus scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Pro Medicus. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Pro Medicus is 8,469.33, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 137.43.Price to Earnings Ratio vs. SectorThe P/E ratio of Pro Medicus is 8,469.33, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 136.16. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverPro Medicus has a short interest ratio ("days to cover") of 3208, which indicates bearish sentiment.Change versus previous monthShort interest in Pro Medicus has recently decreased by 0.37%, indicating that investor sentiment is improving. Dividend0.8 / 5Dividend StrengthWeak Dividend YieldPro Medicus pays a meaningful dividend of 1.63%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthPro Medicus does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Pro Medicus is 133.33%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about Pro Medicus' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares ShortedShort Interest Ratio / Days to CoverPro Medicus has a short interest ratio ("days to cover") of 3208, which indicates bearish sentiment.Change versus previous monthShort interest in Pro Medicus has recently decreased by 0.37%, indicating that investor sentiment is improving. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Pro Medicus this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pro Medicus insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 10.84% of the stock of Pro Medicus is held by institutions.Read more about Pro Medicus' insider trading history. Receive PMCUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pro Medicus and its competitors with MarketBeat's FREE daily newsletter. Email Address PMCUF Stock News HeadlinesVisage Transforms Imaging to the Cloud at RSNA 2024November 12 at 9:53 AM | finance.yahoo.comIs Pro Medicus Limited's (ASX:PME) Latest Stock Performance A Reflection Of Its Financial Health?November 10, 2024 | finance.yahoo.com625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 15, 2024 | Crypto Swap Profits (Ad)Pro Medicus snaffles 5-year contract extension for $32M for RIS technologyOctober 16, 2024 | msn.comPro Medicus Limited (PMCUF) Receives a Hold from WilsonsOctober 8, 2024 | markets.businessinsider.comPro Medicus renews contract with Mercy Health through Visage Imaging subsidiaryOctober 7, 2024 | msn.comGoldman Sachs Reaffirms Their Buy Rating on Pro Medicus Limited (PMCUF)October 7, 2024 | markets.businessinsider.comPro Medicus shares close in on record high amid massive contract winOctober 6, 2024 | msn.comSee More Headlines PMCUF Stock Analysis - Frequently Asked Questions How have PMCUF shares performed this year? Pro Medicus' stock was trading at $64.75 on January 1st, 2024. Since then, PMCUF shares have increased by 96.2% and is now trading at $127.04. View the best growth stocks for 2024 here. How do I buy shares of Pro Medicus? Shares of PMCUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolOTCMKTS:PMCUF CUSIPN/A CIKN/A Webwww.promed.com.au Phone61 3 9429 8800FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio8,469.33 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (OTCMKTS:PMCUF) was last updated on 11/15/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your fi...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYou just voted for a financial crisisI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pro Medicus Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Pro Medicus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.